Stockscreener 앱 받기
64.45
1.47%
0.9403
전일 마감가:
$63.51
열려 있는:
$63.41
하루 거래량:
847.46K
Relative Volume:
0.45
시가총액:
$6.04B
수익:
$1.64B
순이익/손실:
$121.85M
주가수익비율:
41.85
EPS:
1.54
순현금흐름:
$-480.40M
1주 성능:
+4.77%
1개월 성능:
+18.39%
6개월 성능:
-48.45%
1년 성능:
-51.79%
1일 변동 폭
$63.12
$64.54
1주일 범위
$59.62
$64.54
52주 변동 폭
$48.01
$173.25
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
SRPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
64.43 | 6.04B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.22 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
608.93 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
654.05 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.70 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.09 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of HealthEquity, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. - GlobeNewswire Inc.
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus
Oligonucleotide Delivery System Market Key Players Analysis - openPR.com
Ratios Revealed: Decoding Sarepta Therapeutics Inc (SRPT)’s Financial Health - DWinneX
Sarepta Therapeutics Inc [SRPT] stock for 248,203 USD was sold by Nicaise Claude - knoxdaily.com
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth - MSN
Duchenne Muscular Dystrophy Market Forecasted to Surge - openPR.com
Adversity is less terrifying than hope: Sarepta Therapeutics Inc (SRPT) - Sete News
Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now - Yahoo Finance
11 Oversold NASDAQ Stocks to Buy Right Now - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sarepta Therapeutics, Inc. – SRPT - TradingView
Sarepta Therapeutics Inc (SRPT) did well last session? - uspostnews.com
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, In - GuruFocus
Recent Insider Activity Suggests Potential Gains for Sarepta Therapeutics Inc (SRPT) - knoxdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Sarepta Therapeutics Inc (SRPT)’s Market Momentum: Closing Strong at 59.49, Up 0.30 - DWinneX
Cns Specific Antisense Oligonucleotide Market Generated - openPR.com
Sarepta Therapeutics (SRPT): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential - MSN
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Cerity Partners LLC - Defense World
How To Trade (SRPT) - news.stocktradersdaily.com
Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential - Insider Monkey
Get in on Sarepta Therapeutics Inc’s (SRPT) buy-in window today! - Sete News
Why Do Investors Buy Stock In Sarepta Therapeutics Inc (SRPT)? - Marketing Sentinel
Sarepta Therapeutics Inc [SRPT] Stock sold by Insider Nicaise Claude for $0.25 million - knoxdaily.com
SRPT Quantitative Stock Analysis - Nasdaq
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Sarepta: Gene therapy Elevidys has given ‘hope’ to DMD community - Muscular Dystrophy News
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost - MSN
Sarepta Therapeutics Inc (SRPT) produces promising results - uspostnews.com
Sarepta Therapeutics to Announce First Quarter 2025 Financial Re - GuruFocus
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results | SRPT Stock News - GuruFocus
Sarepta Therapeutics To Announce First Quarter 2025 Financial Results - marketscreener.com
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results - Business Wire
Envestnet Asset Management Inc. Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Short Interest Update - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Given New $110.00 Price Target at Piper Sandler - Defense World
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts? - Insider Monkey
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
11 Most Promising Long-Term Stocks According to Analysts - Insider Monkey
Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Piper Sandler Cuts Price Target for Sarepta (SRPT) Amid Elevidys Sales Concerns | SRPT Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Thera - NatLawReview.com
Sarepta (SRPT) Price Target Lowered by BofA Ahead of Q1 Earnings | SRPT Stock News - GuruFocus
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
0.30%
자본화:
|
볼륨(24시간):